Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Y Liu

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
AIDS and Behavior|August 19, 2022
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with MenSusan P Buchbinder, Aaron J Siegler, Kenneth Coleman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2019
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence TestingMatthew A Spinelli, David V Glidden, Peter L Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted GerotherapeuticsPeter L Anderson, Alina Ps Pang, Ryan P Coyle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration ProjectEric C Tang, Eric Vittinghoff, Peter L Anderson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2016
Symptoms, Side Effects and Adherence in the iPrEx Open-Label ExtensionDavid V Glidden, K Rivet Amico, Albert Y Liu, et al.
AIDS and Behavior|June 17, 2015
Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)Patricia A Defechereux, Megha Mehrotra, Albert Y Liu, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2017
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed TherapyPeter L Anderson, Albert Y Liu, Jose R Castillo-Mancilla, et al.
Plos One|August 21, 2019
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil StudyLuana M S Marins, Thiago S Torres, Iuri da C Leite, et al.
The Lancet. HIV|February 12, 2017
Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, BrazilBeatriz Grinsztejn, Emilia M Jalil, Laylla Monteiro, et al.
AIDS and Behavior|August 18, 2016
Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in BrazilBrenda Hoagland, Raquel B De Boni, Ronaldo I Moreira, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
AIDS and Behavior|August 19, 2022
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with MenSusan P Buchbinder, Aaron J Siegler, Kenneth Coleman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2019
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence TestingMatthew A Spinelli, David V Glidden, Peter L Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted GerotherapeuticsPeter L Anderson, Alina Ps Pang, Ryan P Coyle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration ProjectEric C Tang, Eric Vittinghoff, Peter L Anderson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2016
Symptoms, Side Effects and Adherence in the iPrEx Open-Label ExtensionDavid V Glidden, K Rivet Amico, Albert Y Liu, et al.
AIDS and Behavior|June 17, 2015
Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)Patricia A Defechereux, Megha Mehrotra, Albert Y Liu, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2017
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed TherapyPeter L Anderson, Albert Y Liu, Jose R Castillo-Mancilla, et al.
Plos One|August 21, 2019
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil StudyLuana M S Marins, Thiago S Torres, Iuri da C Leite, et al.
The Lancet. HIV|February 12, 2017
Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, BrazilBeatriz Grinsztejn, Emilia M Jalil, Laylla Monteiro, et al.
AIDS and Behavior|August 18, 2016
Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in BrazilBrenda Hoagland, Raquel B De Boni, Ronaldo I Moreira, et al.
Pageof 10